CBP8 PET/MRI
Phase 3Small molecule
CBP8 PET/MRI is one of 8 small molecule programs targeting Myocardial fibrosis. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Myocardial Fibrosis
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaApproved
Invokana
WWim Janssens
Approved
Esbriet
LLegacy Health System
Approved
Aldactone
PfizerPhase 3
Torasemide
Boehringer IngelheimApproved
CBP8 PET/MRI
BBrigham and Women's Hospital
Phase 3
Dihydralazine
UUniversity Medical Center Goettingen
Phase 3
Henagliflozin
TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CBP8 PET/MRI. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- BBrigham and Women's Hospital